VivoSeq
Neurology

Progressive Multifocal Leukoencephalopathy

18

Pipeline Programs↗

4

Active Trials↗

11

Companies Involved↗

Progressive Multifocal Leukoencephalopathy is an emerging landscape with 18 programs across 11 companies. The most active players are United BioPharma, Teva, Eastern Cooperative Oncology Group.

Intelligence

Pipeline Metrics

Competitive Density

46/100

Pipeline Velocity

6/100

Mech. Concentration

27/100

Completion Rate

89/100

Attrition Rate

8/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

U

United BioPharma

1 program

Phase 1Teva logo

Teva

1 program

Phase 2E

Eastern Cooperative Oncology Group

1 program

Phase 2M

Meitheal

1 program

Phase 2Bristol-Myers Squibb logo

Bristol-Myers Squibb

1 program

Phase 2Emergent BioSolutions logo

Emergent BioSolutions

1 program

Phase 2

Pipeline

Programs by Phase

Analysis

Modality Breakdown

79%

Small molecule

11 of 14 classified programs — the dominant modality here.

21%ALL OTHERSMonoclonal antibody214%Protein / enzyme17%

Small molecule leads; the ring shows all 14 classified programs, each share of the total. Modality classified for 100% of 18 pipeline programs.

Analysis

Trial Status

13

clinical trials

Completed8 · 62%
Recruiting3 · 23%
Not yet recruiting1 · 8%
Terminated1 · 8%

Clinical Trials

Trial Activity

13 trials

Central Nervous System Uptake of Anti-CD8+ T Cell Minibodies in Multiple Sclerosis and Progressive Multifocal Leukoencephalopathy
Recruiting·National Institute of Neurological Disorders and Stroke (NINDS)·Phase 1·NCT05849467·15 enrolled
Safety and Tolerability of Intravenous Brincidofovir as an Antiviral for Treatment of Progressive Multifocal Leukoencephalopathy: A Pilot Study
Recruiting·National Institute of Neurological Disorders and Stroke (NINDS)·Phase 2·NCT07511049·24 enrolled
Natural History Study of Progressive Multifocal Leukoencephalopathy (PML)
Recruiting·National Institute of Neurological Disorders and Stroke (NINDS)·N/A·NCT01730131·700 enrolled
Pembrolizumab in Progressive Multifocal Leukoencephalopathy (PML) in Immunocompromised Patients Without HIV Infection
Not yet recruiting·AAssistance Publique - Hôpitaux de Paris·Phase 2/3·NCT06276504·33 enrolled
Dynamics of T Cell Expression of Immune Checkpoint Molecules in Progressive Multifocal Leukoencephalopathy
Completed·UUniversity Hospital, Toulouse·N/A·NCT04453917·22 enrolled
A Pilot Study of the Efficacy of Recombinant Alpha Interferon (IFN-A2b) and Zidovudine (AZT) in the Treatment of Progressive Multifocal Leukoencephalopathy (PML) Complicating HIV-1 Infection
Completed·UUniversity of Miami·N/A·NCT00002270
NT-I7, a Long-Acting Recombinant IL-7 Molecule, as an Immune Reconstitution Strategy for Lymphopenia in Patients With Progressive Multifocal Leukoencephalopathy
Completed·National Institute of Neurological Disorders and Stroke (NINDS)·Phase 1·NCT04781309·12 enrolled
A Study to Evaluate the Use of Cidofovir (an Experimental Drug) for the Treatment of Progressive Multifocal Leukoencephalopathy (PML) in AIDS Patients
Completed·National Institute of Allergy and Infectious Diseases (NIAID)·N/A·NCT00000945·24 enrolled
Safety and Effectiveness of Topotecan HCl to Treat HIV-Infected Patients With AIDS-Related Progressive Multifocal Leukoencephalopathy (PML)
Completed·GSK logoGSK·Phase 2·NCT00002395·54 enrolled
TOPIK Study: A Study to Report Progressive Multifocal Leukoencephalopathy and Other Serious Opportunistic Infections in Natalizumab Treated Participants
Completed·Biogen logoBiogen·N/A·NCT05236777·675 enrolled
Comparison of Anti HIV Drugs Used Alone or in Combination With Cytosine Arabinoside to Treat Progressive Multifocal Leukoencephalopathy (PML) in HIV-Infected Patients
Completed·National Institute of Allergy and Infectious Diseases (NIAID)·Phase 2·NCT00001048·90 enrolled
A Pilot Study of Adoptive Cellular Immunotherapy for Progressive Multifocal Leukoencephalopathy With Ex Vivo Generated Polyomavirus-Specific T-cells
Completed·National Institute of Neurological Disorders and Stroke (NINDS)·Phase 1·NCT02694783·60 enrolled
Study to Explore the Effect of Mefloquine in Participants With Progressive Multifocal Leukoencephalopathy (PML)
Terminated·Biogen logoBiogen·Phase 1/2·NCT00746941·37 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)